Peloton Wealth Strategists Trims Holdings in Danaher Corporation $DHR

Peloton Wealth Strategists cut its holdings in Danaher Corporation (NYSE:DHR) by 2.0% during the first quarter, Holdings Channel reports. The institutional investor owned 5,581 shares of the conglomerate’s stock after selling 115 shares during the quarter. Peloton Wealth Strategists’ holdings in Danaher were worth $1,144,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nuveen LLC purchased a new stake in Danaher during the 1st quarter valued at about $833,941,000. GAMMA Investing LLC grew its position in Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock valued at $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP grew its position in Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Invesco Ltd. grew its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock valued at $309,558,000 after purchasing an additional 1,107,998 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on DHR shares. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Finally, Evercore ISI lowered their target price on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $246.35.

Danaher Price Performance

Shares of NYSE:DHR opened at $198.74 on Tuesday. The firm’s 50 day moving average price is $201.95 and its 200-day moving average price is $199.23. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $142.31 billion, a PE ratio of 42.29, a price-to-earnings-growth ratio of 2.79 and a beta of 0.75.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter in the prior year, the business earned $1.72 EPS. The business’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.